The AI‑driven biotech startup secured $400 million, with backers including OpenAI, Pfizer and Eli Lilly, to accelerate antibody design.

Chai Discovery has closed a $400 million funding round to supercharge its AI‑driven platform for antibody design, signaling a decisive shift by major pharmaceutical players toward machine‑learning‑based drug discovery.

Funding round highlights

The round was led by OpenAI and included strategic investors such as Pfizer, Eli Lilly, and several venture firms. The capital will be deployed to expand the company’s computational infrastructure, hire additional scientists, and accelerate pre‑clinical programs.

  • $400 million total raise
  • Lead investor: OpenAI
  • Key pharma backers: Pfizer, Eli Lilly
  • Additional investors: Andreessen Horowitz, Sequoia Capital

Why AI is winning over blockchain in biotech

While blockchain once promised transparency in clinical data, AI now delivers tangible value by predicting antibody affinity, optimizing lead selection, and shortening discovery timelines. Industry analysts note that machine‑learning models can reduce the early‑stage cost of drug development by up to 30 %.

Chai Discovery’s platform integrates large‑scale protein language models with proprietary data sets, enabling rapid in‑silico screening of millions of antibody candidates. This approach contrasts with earlier blockchain‑focused initiatives that struggled to demonstrate concrete scientific outcomes.

Implications for big pharma

Pharma giants are increasingly allocating capital to AI startups to supplement internal R&D pipelines. Pfizer’s participation underscores its strategy to partner with external innovators, while Eli Lilly aims to leverage Chai’s technology for its oncology and immunology programs.

The infusion of $400 million also positions Chai Discovery as a potential acquisition target, as larger biotech firms seek to integrate advanced AI capabilities without building them from scratch.

“AI is the next frontier for accelerating therapeutic discovery, and Chai Discovery is at the forefront of that transformation,” said a spokesperson for OpenAI.

Read the full coverage at Source coverage.